News News


Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282

Media: Mark Corbae
Tel: 203-682-8288

Sirnaomics News Placeholder 01
June 24, 2010 Sirnaomics Aims to Move Wound-Healing Drug into Phase I Next Year

Having put on the backburner its one-time lead drug-development program in ocular neovascularization disorders, Sirnaomics is now focusing on an siRNA-based treatment for scarless wound healing and anticipates moving the drug into phase I testing.

1 10 11 12